30
Apr

The big biotech party on Wall Street isn’t over yet. Blueprint Medicines, which came out of Third Rock’s stable of startups, made the leap into NASDAQ, selling $147 million in shares in an upsized IPO. Shares went for $18 each, above the $15 to $17 range, providing fresh evidence that investors still have an appetite for early-stage drug developers.

…read more

Source: Third Rock’s Blueprint Medicines scores $147M windfall in another hot IPO

    

0 No comments